Oncology - CurrentMed (Page 6)

Oncology

Myeloid‐Derived LGALS9‐P4HB Immune Interaction Promotes Metastasis in Gastric Cancer Through Enhanced Cell Proliferation and Lipid Metabolism

PMCID: PMC12176694 PMID: 40534096 DOI: 10.1111/jcmm.70661 Journal: Journal of cellular and molecular medicine Publication Date: 2025-6-18 Authors: Zhu X, Zhang Y, Yu A, Xiao X Key Points * Myeloid cell-derived LGALS9 and epithelial cell P4HB interaction is a previously uncharacterized mechanism driving gastric cancer metastasis * Pharmacological P4HB inhibitors

Oncology

The efficacy and therapy management of nab-paclitaxel in the real-world setting for patients with advanced breast cancer – the SERAPHINA study

PMCID: PMC12178961 PMID: 40536732 DOI: 10.1007/s00432-025-06246-2 Journal: Journal of cancer research and clinical oncology Publication Date: 2025-6-19 Authors: Schneeweiss A, Fasching PA, Thill M, van Mackelenbergh M, Marme F, et al. Key Points * Nab-paclitaxel demonstrated consistent efficacy across multiple treatment lines in advanced breast cancer * Median progression-free survival

Oncology

Outcomes Following Transoral Laser Microsurgery for T1b and T2a Glottic Squamous Cell Carcinoma With and Without Anterior Commissure Involvement: A Retrospective Chart Review

PMCID: PMC12177246 PMID: 40530452 DOI: 10.1177/19160216251348424 Journal: Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale Publication Date: 2025-6-18 Authors: Patel D, Taylor V, MacKay C, den Besten C, Rigby MH, et al. Key Points * TLM demonstrates comparable oncological outcomes

Oncology

Repurposing MDM2 inhibitor RG7388 for TP53-mutant NSCLC: a p53-independent pyroptotic mechanism via ROS/p-p38/NOXA/caspase-3/GSDME axis

PMCID: PMC12170848 PMID: 40523886 DOI: 10.1038/s41419-025-07770-2 Journal: Cell death & disease Publication Date: 2025-6-17 Authors: Tang G, Cao X, Chen J, Hui F, Xu N, et al. Key Points * RG7388 exhibits potent anti-tumor effects in TP53-mutant NSCLC through a p53-independent mechanism * Significant dose-dependent reduction in cell viability across

Pharmacology

Treatment with gemcitabine/cisplatin and durvalumab for advanced biliary tract cancer – real-world data from a multicenter German patient population

PMCID: PMC12176970 PMID: 40533571 DOI: 10.1007/s00432-025-06239-1 Journal: Journal of cancer research and clinical oncology Publication Date: 2025-6-18 Authors: Gerhardt F, Müller C, Venerito M, Chater J, Mohr R, et al. Key Points * First real-world validation of ICI-based therapy for advanced biliary tract cancers using gemcitabine/cisplatin and durvalumab

Oncology

Oral Soft Tissue and Jawbone Sarcomas: A Retrospective Clinicopathologic Analysis of 128 Cases from Two Institutions and Comprehensive Literature Review

PMCID: PMC12174025 PMID: 40526340 DOI: 10.1007/s12105-025-01811-0 Journal: Head and neck pathology Publication Date: 2025-6-17 Authors: Argyris PP, Dennis GR, Gopalakrishnan R, Koutlas IG, McNamara KK, et al. Key Points * Osteosarcoma and Kaposi sarcoma collectively represent two-thirds of oral soft tissue and jawbone sarcomas * Male-to-female ratio of 1.5:

Pharmacology

An Acrolein-Based Drug Delivery System Enables Tumor-Specific Sphingosine-1-Phosphate Targeting in Breast Cancer without Lymphocytopenia

PMCID: PMC12174973 PMID: 40528704 DOI: 10.1158/2767-9764.CRC-25-0023 Journal: Cancer research communications Publication Date: 2025-6 Authors: Nagahashi M, Komatsu M, Urano S, Kuroiwa M, Takahashi Y, et al. Key Points * Pro-FTY selectively targets and inhibits breast cancer cells, including multidrug-resistant variants, using an acrolein-responsive drug delivery system * Demonstrated 100%

Pharmacology

Targeting circulating tumor cell‒neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis

PMCID: PMC12175327 PMID: 40528159 DOI: 10.1186/s12951-025-03522-8 Journal: Journal of nanobiotechnology Publication Date: 2025-6-17 Authors: Su Y, Leng M, Yang Q, Jiang W, Xiang G, et al. Key Points * Neutrophil-CTC interactions are a critical mechanism driving cancer metastasis through multiple biological processes * Nanotechnology-based drug delivery systems show promise in

Immunology

Gut Microbiota Reshapes the Tumor Microenvironment and Affects the Efficacy of Colorectal Cancer Immunotherapy

PMCID: PMC12175482 PMID: 40530896 DOI: 10.1002/cam4.70994 Journal: Cancer medicine Publication Date: 2025-6-18 Authors: Wang F, Chen W, Jia Y, He T, Wu S, et al. Key Points * Intestinal microbiota significantly modulates immunotherapy response in colorectal cancer * Specific bacterial strains can enhance CD8+ T cell infiltration and cytotoxicity

Pharmacology

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation

PMCID: PMC12170901 PMID: 40523897 DOI: 10.1038/s41392-025-02274-z Journal: Signal transduction and targeted therapy Publication Date: 2025-6-17 Authors: Ruan DY, Wu HX, Xu Y, Munster PN, Deng Y, et al. Key Points * First study with the highest proportion of Asian mCRC patients receiving a KRAS G12C inhibitor, demonstrating promising anti-tumor

Immunology

Clinical factors associated with growth and neoantigen reactivity of tumor infiltrating lymphocytes from metastatic epithelial cancers

PMCID: PMC12179044 PMID: 40536705 DOI: 10.1007/s00262-025-04091-3 Journal: Cancer immunology, immunotherapy : CII Publication Date: 2025-6-19 Authors: Gustafson AM, Dinerman AJ, Hitscherich KJ, Parkhurst MR, Halas H, et al. Key Points * Lung metastases demonstrated superior TIL growth (95%) compared to other resection sites * 51% of TIL harvests showed high neoantigen

Pharmacology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment

PMCID: PMC12175699 PMID: 40526090 DOI: 10.18632/oncotarget.28744 Journal: Oncotarget Publication Date: 2025 Authors: Hernando-Calvo A, Kurzrock R, Gonzalez NS, Magidi S, Bresson C, et al. Key Points * Comprehensive molecular profiling revealed multiple actionable genetic alterations in mCRC * Personalized treatment strategies proposed, including targeted therapies matching specific mutations * Repeated